Investing News NetworkYour trusted source for investing success

Videos
Companies
Press Releases
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Private Placements
Trending
Trending Articles

Could the Silver Price Really Hit US$100 per Ounce? (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Top 10 Countries for Natural Gas Production (Updated 2024)

Top 10 Copper-producing Companies (Updated 2024)

7 Biggest Lithium-mining Companies

Top 7 Canadian Lithium Stocks of 2024

Hydrogen Stocks: 9 Biggest Companies

Where Does Tesla Get its Lithium? (Updated 2024)

11 Canadian Cryptocurrency ETFs (Updated 2024)

Trending Press Releases

Galan Lithium Limited (ASX: GLN) – Trading Halt

Edison Lithium Expands Portfolio with Acquisition of Additional Sodium Brine Claim in Saskatchewan

Bitcoin Well Launches Cash Vouchers For Canadian Customers

Osisko Metals Reports Preliminary Metallurgical Testwork Results From Gaspé Copper

Mineral Resource Update – Mt Boppy Gold Project

Victory Battery Metals Corp. Options Kachiwiss Uranium Project and Other Uranium Anomalies

More Press Releases
Trending Companies

Trident Royalties PLC

TDTRF

Galan Lithium

GLN:AU

Impact Minerals Limited

IPT:AU

Ramp Metals

RAMP:CC
More Companies
Trending Reports

2024 Uranium Outlook (Updated for Q2)

2024 Lithium Market Outlook

2024 EV Market Outlook Report

2024 Copper Market Outlook (Australia Ed.)

More Outlook Reports
Resource
Resource
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Tech
Tech
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Life Science
Life Science
Popular Lists
Investing Ideas
Outlook Reports
Investing Guides
Gold
Copper
Uranium
Oil and Gas
Artificial Intelligence
Biotech
loader

Aclaris Therapeutics Inc.

NASDAQ:ACRS
Press Releases

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

×